Verona Pharma PLC (VRNA)
12.07
+0.59
(+5.14%)
USD |
NASDAQ |
May 31, 16:00
12.09
+0.02
(+0.17%)
Pre-Market: 20:00
Verona Pharma Research and Development Expense (Quarterly): 6.764M for March 31, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 6.764M |
| December 31, 2023 | 4.122M |
| September 30, 2023 | 2.958M |
| June 30, 2023 | -2.474M |
| March 31, 2023 | 12.61M |
| December 31, 2022 | 6.838M |
| September 30, 2022 | 9.838M |
| June 30, 2022 | 14.98M |
| March 31, 2022 | 17.62M |
| December 31, 2021 | 22.71M |
| September 30, 2021 | 22.56M |
| June 30, 2021 | 20.56M |
| March 31, 2021 | 13.57M |
| December 31, 2020 | 16.25M |
| September 30, 2020 | 12.82M |
| June 30, 2020 | 7.811M |
| Date | Value |
|---|---|
| March 31, 2020 | 7.622M |
| December 31, 2019 | 7.217M |
| September 30, 2019 | 14.74M |
| June 30, 2019 | 12.57M |
| March 31, 2019 | 7.732M |
| December 31, 2018 | 6.699M |
| September 30, 2018 | 6.965M |
| June 30, 2018 | 5.075M |
| March 31, 2018 | 6.196M |
| December 31, 2017 | 13.26M |
| September 30, 2017 | 8.152M |
| June 30, 2017 | 6.294M |
| March 31, 2017 | 3.874M |
| December 31, 2016 | 2.122M |
| September 30, 2016 | 1.836M |
| June 30, 2016 | 0.6969M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
-2.474M
Minimum
Jun 2023
22.71M
Maximum
Dec 2021
11.58M
Average
12.59M
Median
Research and Development Expense (Quarterly) Benchmarks
| Biodexa Pharmaceuticals Plc | -- |
| NuCana PLC | 8.604M |
| Bicycle Therapeutics PLC | 34.86M |
| TC BioPharm (Holdings) PLC | 1.648M |
| Adaptimmune Therapeutics PLC | 35.21M |